Inter-synergized neuroprotection of costunolide engineered bone marrow mesenchymal stem cells targeting system

[Display omitted] Treatment of stroke remains difficult due to the unsatisfactory or unlocalized delivery of small molecule- and cell-based therapeutics in injured brain tissues. This is particularly the case for costunolide (Cos), which is highly neuroprotective and anti-inflammatory but finds grea...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2023-05, Vol.639, p.122823-122823, Article 122823
Main Authors: Mao, Zhiyuan, Liu, Yang, Lv, Xiaojing, Jiang, Yu, Zhang, Qun, Yang, Li, Jiang, Hezhong, Tan, Renxiang, Tan, Rui
Format: Article
Language:English
Subjects:
Animals
Bone Marrow Cells
Bone marrow mesenchymal stem cells
Costunolide
Inter-promoted neuroprotection
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
Neuroprotection
Rats
Rats, Sprague-Dawley
Recellularization
Reproducibility of Results
Stroke
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Treatment of stroke remains difficult due to the unsatisfactory or unlocalized delivery of small molecule- and cell-based therapeutics in injured brain tissues. This is particularly the case for costunolide (Cos), which is highly neuroprotective and anti-inflammatory but finds great difficulty in reaching the brain. Here, we present that Cos induces the differentiation of bone marrow mesenchymal stem cells (bMSCs) into glia-like cells (C-bMSCs) capable of secreting neurotrophic factors and homing to injured brain tissues. By taking advantage of the homing effect, Cos and C-bMSCs were simultaneously funneled into the damaged brain by: (i) preparing Cos micelles (Cos-M) through entrapping Cos into the amphiphilic copolymer mPEG-PLGA [poly(ethylene oxide) monomethyl ether-poly(lactide-co-glycolide)], and (ii) incorporating Cos-M into C-bMSCs to give an intravenously injectable cell-like composite termed Cos@C-bMSCs, which displayed the inter-synergized neuroprotective efficacy in the cerebral ischemia reperfusion (CIR) injured rats. As desired, in the injured brain area, Cos@C-bMSCs simultaneously released Cos and C-bMSCs (glia-like cells) to repair the injured brain and to secret neurotrophic factors such as nerve growth factor (NGF). In view of the availability and reliability of autologous MSCs, the proof-of-concept design, development, and in vivo efficacy of Cos@C-bMSCs signify a movement in our management of brain damages.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2023.122823